Core Viewpoint - State Street Corporation (STT) has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system emphasizes the correlation between changes in earnings estimates and stock price movements, making it a valuable tool for investors [2][4]. - An increase in earnings estimates typically leads to higher fair value calculations by institutional investors, resulting in buying or selling pressure that affects stock prices [4]. Company Performance and Outlook - The recent upgrade for State Street reflects an improvement in its underlying business, suggesting that investors may respond positively by driving the stock price higher [5]. - Analysts have raised their earnings estimates for State Street, with the Zacks Consensus Estimate increasing by 2.7% over the past three months [8]. Zacks Rank System - The Zacks Rank system categorizes stocks based on earnings estimate revisions, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7]. - State Street's upgrade to Zacks Rank 1 places it in the top 5% of Zacks-covered stocks, indicating strong potential for market-beating returns in the near term [10].

Core Viewpoint - New Found Gold Corp. (NFGC) has received a Zacks Rank 2 (Buy) upgrade due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with stock price movements, particularly influenced by institutional investors [4][6]. - An increase in earnings estimates typically leads to higher fair value calculations for stocks, prompting institutional investors to buy or sell accordingly, thus affecting stock prices [4]. Company Performance and Outlook - The recent upgrade for New Found Gold Corp. indicates an improvement in the company's underlying business, suggesting that investors may respond positively by driving the stock price higher [5]. - For the fiscal year ending December 2025, New Found Gold Corp. is expected to earn -$0.13 per share, which remains unchanged from the previous year, but the Zacks Consensus Estimate has increased by 43.5% over the past three months [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have generated an average annual return of +25% since 1988 [7]. - The upgrade to Zacks Rank 2 places New Found Gold Corp. in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10].

Core Viewpoint - Canada Goose (GOOS) has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][2]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [3][5]. - Institutional investors utilize earnings estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [3]. Canada Goose's Earnings Outlook - The upgrade for Canada Goose reflects an improvement in its underlying business, with rising earnings estimates expected to drive the stock price higher [4]. - For the fiscal year ending March 2026, Canada Goose is projected to earn $0.88 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 1.7% over the past three months [7]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [6]. - Canada Goose's upgrade to Zacks Rank 1 places it in the top 5% of Zacks-covered stocks, indicating strong potential for near-term price appreciation [9].

Core Viewpoint - Geely Automobile Holdings Ltd. has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][4][6]. Earnings Estimates and Ratings - The Zacks rating system is primarily driven by changes in a company's earnings picture, with the Zacks Consensus Estimate reflecting EPS estimates from sell-side analysts [2][3]. - The recent upgrade for Geely Automobile suggests an improvement in its underlying business, which is expected to positively impact its stock price [4][6]. Impact of Earnings Estimate Revisions - Changes in future earnings potential, as indicated by earnings estimate revisions, are strongly correlated with near-term stock price movements, particularly due to institutional investors' reliance on these estimates for valuation [5][7]. - For Geely Automobile, the Zacks Consensus Estimate for the fiscal year ending December 2025 is projected at $4.12 per share, unchanged from the previous year, but has seen a 7% increase in estimates over the past three months [9]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [8]. - Geely Automobile's upgrade to Zacks Rank 1 places it in the top 5% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10][11].

Investors might want to bet on Astrana Health, Inc. (ASTH) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Since a c ...

Core Viewpoint - Cadence (CADE) has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - Institutional investors often adjust their valuations based on earnings estimates, leading to significant stock price movements when they buy or sell large amounts of shares [4]. Cadence's Earnings Outlook - The upgrade for Cadence reflects an improvement in the company's underlying business, which is expected to drive the stock price higher as investors recognize this trend [5][10]. - For the fiscal year ending December 2025, Cadence is projected to earn $2.92 per share, with a 5.9% increase in the Zacks Consensus Estimate over the past three months [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7]. - Only the top 5% of Zacks-covered stocks receive a "Strong Buy" rating, indicating superior earnings estimate revisions and potential for market-beating returns [9][10].

Company Overview - Rhythm Pharmaceuticals, Inc. (RYTM) shares increased by 36.6% in the last trading session, closing at $89, with notable trading volume compared to typical sessions [1] - The stock had previously experienced a 3.3% loss over the past four weeks [1] Recent Developments - The stock's rally followed the announcement of positive top-line data from a phase II study of the investigational oral melanocortin-4 receptor (MC4R) agonist, bivamelagon, for patients with acquired hypothalamic obesity [2] - The study results indicated statistically significant and clinically meaningful reductions in body mass index after 14 weeks of treatment with bivamelagon [2] Financial Expectations - The company is projected to report a quarterly loss of $0.64 per share, reflecting a year-over-year change of -16.4% [3] - Expected revenues for the upcoming report are $43.76 million, which represents a 50.5% increase from the same quarter last year [3] - The consensus EPS estimate for the quarter has remained unchanged over the last 30 days, indicating that stock price movements may not continue without trends in earnings estimate revisions [4] Industry Context - Rhythm Pharmaceuticals is part of the Zacks Medical - Biomedical and Genetics industry, which includes other companies like EyePoint Pharmaceuticals (EYPT) [5] - EYPT shares closed 10.2% higher at $10.96, with an 8% return over the past month [5] - EYPT's consensus EPS estimate for the upcoming report has also remained unchanged at -$0.67, representing a -15.5% change from the previous year [6]

Core Viewpoint - Red Robin (RRGB) has shown an 8.1% increase in stock price over the past four weeks, with a mean price target of $9.38 indicating a potential upside of 49.1% from the current price of $6.29 [1] Price Targets and Analyst Estimates - The mean estimate consists of four short-term price targets with a standard deviation of $3.94, where the lowest estimate is $3.50 (44.4% decline) and the highest is $12.00 (90.8% increase) [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about RRGB's earnings prospects, as indicated by a positive trend in earnings estimate revisions [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 14.5%, with one estimate moving higher and no negative revisions [12] - RRGB holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] Conclusion on Price Targets - While the consensus price target may not be a reliable indicator of the stock's potential gain, it does provide a directional guide for price movement [14]

Company Overview - Vir Biotechnology, Inc. (VIR) shares increased by 11.9% to close at $5.93, with trading volume significantly higher than usual, contrasting with a 2.2% loss over the past four weeks [1][2] Pipeline and Development - The rise in stock price is linked to positive investor sentiment regarding tobevibart, Vir Biotechnology's late-stage pipeline candidate, which is in a phase III ECLIPSE 1 study for chronic hepatitis delta (CHD) treatment [2] - The company is preparing to start a phase III ECLIPSE 2 study to evaluate the efficacy and safety of switching to tobevibart and elebsiran for CHD patients not achieving viral suppression with bulevirtide [2] Financial Expectations - The upcoming quarterly report is expected to show a loss of $0.74 per share, reflecting a year-over-year increase of 27.5%, while revenues are projected at $7.05 million, up 128.8% from the previous year [3] - The consensus EPS estimate for the quarter has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] Industry Context - Vir Biotechnology operates within the Zacks Medical - Biomedical and Genetics industry, which includes other companies like Opus Genetics, Inc. (IRD), that also has a Zacks Rank of 2 (Buy) [4][5]

Company Overview - TopBuild shares increased by 6.1% to close at $378.8, supported by strong trading volume, and have gained 15.3% over the past four weeks [1][2] - The company announced an $810 million cash acquisition of Progressive Roofing, which is expected to enhance its position in the commercial roofing segment [2] Financial Performance - TopBuild is projected to report quarterly earnings of $5.10 per share, reflecting a year-over-year decline of 5.9%, with expected revenues of $1.29 billion, down 5.5% from the previous year [3] - The consensus EPS estimate for TopBuild has remained unchanged over the last 30 days, indicating stability in earnings expectations [4] Industry Context - TopBuild is part of the Zacks Building Products - Miscellaneous industry, which includes other companies like Janus International Group, Inc. [5] - Janus International Group's consensus EPS estimate has also remained unchanged at $0.15, representing a year-over-year decline of 28.6% [6]